Nitrosative stress drives heart failure with preserved ejection fraction

Heart failure with preserved ejection fraction (HFpEF) is a common syndrome with high morbidity and mortality for which there are no evidence-based therapies. Here we report that concomitant metabolic and hypertensive stress in mice—elicited by a combination of high-fat diet and inhibition of constitutive nitric oxide synthase using Nω-nitro-l-arginine methyl ester (l-NAME)—recapitulates the numerous systemic and cardiovascular features of HFpEF in humans. Expression of one of the unfolded protein response effectors, the spliced form of X-box-binding protein 1 (XBP1s), was reduced in the myocardium of our rodent model and in humans with HFpEF. Mechanistically, the decrease in XBP1s resulted from increased activity of inducible nitric oxide synthase (iNOS) and S-nitrosylation of the endonuclease inositol-requiring protein 1α (IRE1α), culminating in defective XBP1 splicing. Pharmacological or genetic suppression of iNOS, or cardiomyocyte-restricted overexpression of XBP1s, each ameliorated the HFpEF phenotype. We report that iNOS-driven dysregulation of the IRE1α–XBP1 pathway is a crucial mechanism of cardiomyocyte dysfunction in HFpEF.iNOS-driven dysregulation of the IRE1α–XBP1 pathway leads to cardiomyocyte dysfunction in mice and recapitulates the systemic and cardiovascular features of human heart failure with preserved ejection fraction.

[1]  R. Kaufman,et al.  IRE1α prevents hepatic steatosis by processing and promoting the degradation of select microRNAs , 2018, Science Signaling.

[2]  B. Pieske,et al.  Novel pathomechanisms of cardiomyocyte dysfunction in a model of heart failure with preserved ejection fraction , 2016, European journal of heart failure.

[3]  Gabriel A. Koepp,et al.  Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. , 2015, The New England journal of medicine.

[4]  D. Kass,et al.  Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. , 2014, Circulation research.

[5]  J. Chirinos,et al.  The Nitrate-Nitrite-NO Pathway and Its Implications for Heart Failure and Preserved Ejection Fraction , 2016, Current Heart Failure Reports.

[6]  D. Kass,et al.  Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap , 2016, Circulation.

[7]  E. Olson,et al.  Suppression of Class I and II Histone Deacetylases Blunts Pressure-Overload Cardiac Hypertrophy , 2006, Circulation.

[8]  E. Olson,et al.  Calcineurin Is Necessary for the Maintenance but Not Embryonic Development of Slow Muscle Fibers , 2005, Molecular and Cellular Biology.

[9]  M. Currie,et al.  L-N6-(1-iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase. , 1994, Journal of medicinal chemistry.

[10]  E. Garvey,et al.  Selective inhibition of constitutive nitric oxide synthase by L-NG-nitroarginine. , 1993, Biochemistry.

[11]  E. Braunwald,et al.  Recognizing worsening chronic heart failure as an entity and an end point in clinical trials. , 2014, JAMA.

[12]  N. Houstis,et al.  Why Don't We Have Proven Treatments for HFpEF? , 2017, Circulation research.

[13]  W. Paulus,et al.  A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.

[14]  Joseph A. Hill,et al.  Protein quality control and metabolism: bidirectional control in the heart. , 2015, Cell metabolism.

[15]  H. Ischiropoulos,et al.  Regulation of Protein Function and Signaling by Reversible Cysteine S-Nitrosylation* , 2013, The Journal of Biological Chemistry.

[16]  B. Rothermel,et al.  Differential activation of stress-response signaling in load-induced cardiac hypertrophy and failure. , 2005, Physiological genomics.

[17]  S. Gygi,et al.  S-Nitrosylation links obesity-associated inflammation to endoplasmic reticulum dysfunction , 2015, Science.

[18]  I. Bernátová,et al.  L-NAME in the cardiovascular system — nitric oxide synthase activator? , 2012, Pharmacological reports : PR.

[19]  V. Melenovský,et al.  Sodium Nitrite Improves Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction. , 2015, Journal of the American College of Cardiology.

[20]  S. Hazen,et al.  Target-Selective Protein S-Nitrosylation by Sequence Motif Recognition , 2014, Cell.

[21]  Shannon M. Dunlay,et al.  Epidemiology of heart failure with preserved ejection fraction , 2017, Nature Reviews Cardiology.

[22]  R. Townsend,et al.  Isosorbide Dinitrate, With or Without Hydralazine, Does Not Reduce Wave Reflections, Left Ventricular Hypertrophy, or Myocardial Fibrosis in Patients With Heart Failure With Preserved Ejection Fraction , 2017, Journal of the American Heart Association.

[23]  A. Criollo,et al.  Spliced X-Box Binding Protein 1 Couples the Unfolded Protein Response to Hexosamine Biosynthetic Pathway , 2014, Cell.

[24]  Jian Huang,et al.  Myosin light chain kinase and myosin phosphorylation effect frequency-dependent potentiation of skeletal muscle contraction. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  E. González-López,et al.  Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. , 2015, European heart journal.

[26]  J. Richardson,et al.  Cardiac autophagy is a maladaptive response to hemodynamic stress. , 2007, The Journal of clinical investigation.

[27]  H. Granzier,et al.  Experimentally Increasing the Compliance of Titin Through RNA Binding Motif-20 (RBM20) Inhibition Improves Diastolic Function In a Mouse Model of Heart Failure With Preserved Ejection Fraction , 2016, Circulation.